Tuesday, Nektar Therapeutics (NKTR), a biopharmaceutical company, announced starting of dosing in a Phase 1 dose-escalation study of NKTR-105 in patients with refractory solid tumors, who have failed in all prior available therapies.
The San Carlos, California - based company noted that NKTR-105 is a PEGlylated form of docetaxel and a versatile chemotherapy agent. The compound is currently approved for breast, non-small cell lung, prostate, gastric and head and neck cancers.
The company noted that the compound has a prolonged half life and tumor exposure compared to docetaxel. Nektar expects that its advanced polymer conjugate technology can be used to optimize the bioactivity of the drugs and increase the sustained exposure of active drug to tumor cells in the body.
The Phase 1 study in around 30 patients will assess the safety, pharmacokinetics and anti-tumor activity of NKTR-105. The company will study the potential of the compound to expand therapeutic options in oncology treatment.
NKTR is currently trading at $4.77, down $0.16 or 3.25% on a volume of 163K shares.
For comments and feedback contact: editorial@rttnews.com
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.